| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 49 companies in the Life Sciences Tools & Services industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 14, 2022 | RVTY Revvity, Inc. | Tereau Daniel R69 | Please See Remarks | Sell | 6,696 | $165.84 | $1,110,452.58 | -5.7% | -15.0% | -23.9% | |
| Mar 11, 2022 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 100,000 | $3.13 | $312,864.69 | - | -12.2% | -60.3% | |
| Mar 10, 2022 | GH Guardant Health, Inc. | Meresman Stanley J75 | Director | Sell | 4,934 | $58.74 | $289,823.16 | -54.9% | -28.1% | -57.4% | |
| Mar 10, 2022 | PRPH Prophase Labs, Inc. | Barr Jason Michael | Director | Buy | 750 | $6.48 | $4,860.00 | +2.5% | +78.0% | +4.0% | |
| Mar 10, 2022 | NTRA Natera, Inc. | Brophy Michael Burkes47 | Chief Financial Officer | Sell | 1,197 | $42.16 | $50,465.52 | -1.5% | -8.8% | +27.0% | |
| Mar 10, 2022 | NTRA Natera, Inc. | Chapman Steven Leonard56 | CEO And President | Sell | 1,147 | $42.16 | $48,357.52 | -2.0% | -8.8% | +27.0% | |
| Mar 10, 2022 | NTRA Natera, Inc. | Rabinowitz Daniel48 | Sec. And Chief Legal Officer | Sell | 884 | $42.16 | $37,269.44 | -0.6% | -8.8% | +27.0% | |
| Mar 10, 2022 | NTRA Natera, Inc. | Sheena Jonathan46 | Director, Co-founder | Sell | 694 | $42.16 | $29,259.04 | -0.1% | -8.8% | +27.0% | |
| Mar 9, 2022 | CDNA Caredx, Inc. | Goldberg Michael85 | Director | Sell | 500 | $33.41 | $16,704.00 | -0.8% | -25.0% | -71.3% | |
| Mar 9, 2022 | CDNA Caredx, Inc. | Colon Grace71 | Director | Sell | 1,393 | $34.56 | $48,146.12 | -15.3% | -25.0% | -71.3% | |
| Mar 7, 2022 | NEO Neogenomics Inc | Bonello William | Chief Financial Officer | Sell | 3,209 | $18.29 | $58,692.61 | -3.2% | -55.7% | +0.6% | |
| Mar 7, 2022 | CDNA Caredx, Inc. | Maag Peter84 | Director | Sell | 10,000 | $32.81 | $328,062.55 | -1.6% | -24.4% | -67.0% | |
| Mar 7, 2022 | XWEL Xwell, Inc. | Bernstein Bruce58 | Director | Sell | 15,000 | $1.00 | $14,928.00 | -2.0% | -24.2% | -56.0% | |
| Mar 4, 2022 | MTD Mettler Toledo International Inc/ | Aggersbjerg Peter54 | Head Of Divisions | Sell | 1,000 | $1,386.53 | $1,386,530.00 | -100% | -4.5% | +8.6% | |
| Mar 4, 2022 | VCYT Veracyte, Inc. | Kennedy Giulia C78 | Chief Scientific &Med Officer | Sell | 23,003 | $25.12 | $577,782.85 | -10.8% | -26.4% | -0.1% | |
| Mar 3, 2022 | FLGT Fulgent Genetics, Inc. | Kim Paul77 | CFO And Treasurer | Sell | 454 | $56.31 | $25,563.88 | -0.3% | -4.2% | -39.9% | |
| Mar 3, 2022 | TWST Twist Bioscience Corp | Thorburn James M84 | Chief Financial Officer | Sell | 3,517 | $52.35 | $184,103.19 | -2.4% | -41.0% | -62.9% | |
| Mar 3, 2022 | CRL Charles River Laboratories International, Inc. | Smith David Ross63 | Corporate Executive VP &CFO | Sell | 8,965 | $282.53 | $2,532,920.58 | -6.1% | -19.2% | -18.4% | |
| Mar 3, 2022 | PSNL Personalis, Inc. | Lightspeed Venture Partners Select Iv, L.P. | Affiliate Of 10% Owner | Buy | 314,750 | $9.86 | $3,102,973.57 | +8.7% | -63.3% | -71.5% | |
| Mar 2, 2022 | MTD Mettler Toledo International Inc/ | Filliol Olivier A71 | Director | Sell | 12,500 | $1,390.27 | $17,378,401.08 | -2.5% | -7.3% | +6.6% | |
| Mar 2, 2022 | PSNL Personalis, Inc. | Chen Richard70 | Chief Medical Officer | Sell | 471 | $10.18 | $4,794.78 | -0.3% | -60.4% | -73.8% | |
| Mar 2, 2022 | PSNL Personalis, Inc. | Tachibana Aaron68 | Chief Financial Officer | Sell | 4,511 | $10.18 | $45,921.98 | -1.8% | -60.4% | -73.8% | |
| Mar 1, 2022 | PRPO Precipio, Inc. | Sabet Ahmed Zaki47 | Chief Operating Officer | Buy | 327 | $1.54 | $504.66 | +6.2% | -23.5% | -49.7% | |
| Mar 1, 2022 | PRPO Precipio, Inc. | Danieli Ilan | Chief Executive Officer | Buy | 3,268 | $1.55 | $5,060.50 | +12.4% | -23.5% | -49.7% | |
| Mar 1, 2022 | TMO Thermo Fisher Scientific Inc. | Lagarde Michel62 | Executive Vice President &COO | Sell | 6,100 | $541.29 | $3,301,890.00 | -15.7% | +4.6% | -0.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.